Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Executive Summary
Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.
You may also be interested in...
AbbVie: Competitor Pricing, Humira Formulary Placement Will Dictate US Biosimilars Impact
Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.
AbbVie: Competitor Pricing, Humira Formulary Placement Will Dictate US Biosimilars Impact
Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
AbbVie boosted its revenue guidance, increasing its longer-term Humira forecast from $18bn in 2020 to $21bn, raising the bar for drugs that will make up for revenue lost when biosimilar competition arrives in five years.